Search

Your search keyword '"Bolaji, Olayiwola Akeem"' showing total 14 results
Start Over Author "Bolaji, Olayiwola Akeem"
14 results on '"Bolaji, Olayiwola Akeem"'

3. ATRIAL FIBRILLATION PATIENT PERSPECTIVE SURVEY ON ALTERNATIVE SETTINGS FOR ANTIARRHYTHMIC DRUG INITIATION

Author

Navara, Rachita, Chen, Devon, Lee, Matthew, Devgun, Jasneet, Hsieh, Yi-Ting, Cheung, Christopher, Bolaji, Olayiwola Akeem, Ouedraogo, Faizal, Markson, Favour, Ozkan, Ecem, Samikanu, Luke, Asfaha, Dina Medhanie, Kheiri, Babikir, Paudel, Bishow Mohan, Dopierala, Maria, Gupta, Mansha, Ravuri, Riya, Ananth, Esha, Sheth, Sujay, and Patel, Kunj

Published
2024
Full Text
View/download PDF

7. IN-HOSPITAL OUTCOMES OF OUT OF HOSPITAL CARDIAC ARREST SURVIVORS TREATED WITH TARGETED TEMPERATURE MANAGEMENT. A PROPENSITY MATCHED COHORT ANALYSIS

Author

Evbayekha, Endurance O., Kharsa, Antoine, Sajja, Jayadev, Desai, Purav, Bastidas, Leonela, Nriagu, Bede N., Idowu, Abiodun Benjamin, Bolaji, Olayiwola Akeem, Ouedraogo, Faizal, Adabale, Olanrewaju, Okorare, Ovie, Antia, Akanimo, Rajak, Kripa, Jumbo, Unwam Ekpuk, Alugba, Gabriel, Ubokudom, Daniel Anthony, Ullah, Aman, Gbegbaje, Oghenetejiri, Nair, Ambica Vivek, Jaiswal, Vikash, Okoh, Alexis K., and LaRue, Shane

Published
2024
Full Text
View/download PDF

8. UNDERUTILIZATION OF TRANSCATHETER VALVE REPLACEMENT/REPAIR AMONG PATIENTS LIVING WITH HIV ADMITTED TO THE US HOSPITALS WITH VALVULAR HEART DISEASES AND FACTORS ASSOCIATED WITH A HIGH ODDS OF UNDERGOING TRANSCATHETER VALVE PROCEDURES: A CROSS-SECTIONAL STUDY

Author

Shoar, Saeed, Razek, Nader Abdel, Elebasy, Mohamed, Aboeldahb, Moataz, Ammar, Amro, Bolaji, Olayiwola Akeem, Chaudhary, Ashok, Modukuru, Venkat, Asadi, Mohammad Sadegh, and Sharma, Samin K.

Published
2024
Full Text
View/download PDF

12. PREDICTIVE FACTORS FOR ADVERSE OUTCOMES IN ATRIAL FIBRILLATION PATIENTS WITH SOTALOL AND DOFETILIDE INITIATION

Author

Navara, Rachita, Paudel, Bishow Mohan, Adhaduk, Mehul, Devgun, Jasneet, Cheung, Christopher, Dopierala, Maria, Chen, Devon, Hsieh, Yi-Ting, Samikanu, Luke Bharane, Ozkan, Ecem, Bolaji, Olayiwola Akeem, Ouedraogo, Faizal, Markson, Favour, Asfaha, Dina Medhanie, Kheiri, Babikir, Sheth, Sujay, Ananth, Esha, Ravuri, Riya, and Patel, Kunj

Published
2024
Full Text
View/download PDF

14. Tacrolimus-induced posterior reversible encephalopathy syndrome following liver transplantation.

Author

Dilibe A, Subramanian L, Poyser TA, Oriaifo O, Brady R, Srikanth S, Adabale O, Bolaji OA, and Ali H

Abstract

In this editorial, we talk about a compelling case focusing on posterior reversible encephalopathy syndrome (PRES) as a complication in patients undergoing liver transplantation and treated with Tacrolimus. Tacrolimus (FK 506), derived from Streptomyces tsukubaensis , is a potent immunosuppressive macrolide. It inhibits T-cell transcription by binding to FK-binding protein, and is able to amplify glucocorticoid and progesterone effects. Tacrolimus effectively prevents allograft rejection in transplant patients but has adverse effects such as Tacrolimus-related PRES. PRES presents with various neurological symptoms alongside elevated blood pressure, and is primarily characterized by vasogenic edema on neuroimaging. While computed tomography detects initial lesions, magnetic resonance imaging, especially the Fluid-Attenuated Inversion Recovery sequence, is superior for diagnosing cortical and subcortical edema. Our discussion centers on the incidence of PRES in solid organ transplant recipients, which ranges between 0.5 to 5 +ACU-, with varying presentations, from seizures to visual disturbances. The case of a 66-year-old male status post liver transplantation highlights the diagnostic and management challenges associated with Tacrolimus-related PRES. Radiographically evident in the parietal and occipital lobes, PRES underlines the need for heightened vigilance among healthcare providers. This editorial emphasizes the importance of early recognition, accurate diagnosis, and effective management of PRES to optimize outcomes in liver transplant patients. The case further explores the balance between the efficacy of immunosuppression with Tacrolimus and its potential neurological risks, underlining the necessity for careful monitoring and intervention strategies in this patient population., Competing Interests: Conflict-of-interest statement: No conflicts of interests., (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results